Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - exemestane, quantity: 25 mg - tablet, sugar coated - excipient ingredients: silicon dioxide; crospovidone; hypromellose; magnesium carbonate hydrate; mannitol; microcrystalline cellulose; methyl hydroxybenzoate; macrogol 6000; polysorbate 80; polyvinyl alcohol; sodium starch glycollate; sucrose; titanium dioxide; cetyl esters wax; purified talc; carnauba wax; shellac; iron oxide black; magnesium stearate; purified water; sorbic acid; dimeticone 100; dimeticonol; benzoic acid - aromasin is indicated for the sequential adjuvant treatment of estrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy.,aromasin is indicated for the treatment of estrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-estrogen therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cabergoline 0.5mg - tablet - 0.5 mg - active: cabergoline 0.5mg excipient: lactose leucine - prevention of the onset of lactation in the puerperium only for clearly defined medical reasons: dostinex is indicated for the inhibition of physiological lactation soon after delivery. 1. after parturition, when breast feeding is contraindicated due to medical reasons related to the mother or the new-born. 2.after stillbirth or abortion.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cabergoline -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cabergoline -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - cabergoline -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cabergoline, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: leucine; lactose - indications as at 10 june 2004 : inhibition of physiological lactation - dostinex is indicated for the prevention of the onset of physiological lactation in the puerperium for clearly defined medical reasons. treatment of hyperprolactinemic disorders - dostinex is indicated for the treatment of pathological hyperprolactinaemia.

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leukemia, hairy cell - antineoplastic agents - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cabergoline -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cabergoline -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - pergolide mesylate -